“A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis”, J of Skin, vol. 2, no. S1, p. S29, Feb. 2018, doi: 10.25251/skin.2.supp.28.